Drugs / Ado-trastuzumab (T) emtansine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04620187 | Dec 2020 → Feb 2028 expected | salivary gland cancer | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ado-trastuzumab (T) emtansine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620187 ↗ |
| Known as | T-DM1 | “This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when...” NCT04620187 ↗ |
| Route | Intravenous | “The drug is a HER-2 antibody that is bound to a chemotherapy agent (DM1) and delivered intravenously.” NCT04620187 ↗ |
| Target | ERBB2 | “T-DM1 is a specialized antibody targeting HER-2 (a protein that is expressed in some breast and salivary gland cancers).” NCT04620187 ↗ |